{"name":"Oculis","slug":"oculis","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OCS-01","genericName":"OCS-01","slug":"ocs-01","indication":"Treatment of neovascular (wet) age-related macular degeneration","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Dexamethasone nanoparticles eye drops","genericName":"Dexamethasone nanoparticles eye drops","slug":"dexamethasone-nanoparticles-eye-drops","indication":"Uveitis","status":"phase_2"}]}],"pipeline":[{"name":"OCS-01","genericName":"OCS-01","slug":"ocs-01","phase":"phase_3","mechanism":"OCS-01 is an anti-vascular endothelial growth factor (VEGF) inhibitor.","indications":["Treatment of neovascular (wet) age-related macular degeneration"],"catalyst":""},{"name":"Dexamethasone nanoparticles eye drops","genericName":"Dexamethasone nanoparticles eye drops","slug":"dexamethasone-nanoparticles-eye-drops","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Uveitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"regulatory","source":"simplywall.st","summary":"Assessing Oculis Holding (OCS) Valuation After EMA PRIME Designation For Privosegtor - simplywall.st","headline":"Assessing Oculis Holding (OCS) Valuation After EMA PRIME Designation For Privosegtor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOOTgwdktmVnhHLWNFYWRrX2NmQ29jS0JkU0J4OGdyVTVYWlhpakdBbkVrT0h6YlNXRmVPcXM2elhKdXJUUmc3X25IMnFZUTBxMXhIVHcwZ0tsb2t6MDNJTS1wOXhxMGlVbkhZZ3ZMSEVKc3NDeTJKd0JnSzZBYkh2bzFPVm5aOGt5a1VSR1ljNUtaUDdGVmNLTS1jbw?oc=5","date":"2026-01-06","type":"pipeline","source":"The Pharma Letter","summary":"Oculis’ privosegtor moves closer to $7 billion market - The Pharma Letter","headline":"Oculis’ privosegtor moves closer to $7 billion market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQMnBZa3h1UFNSQjFlQTdoSFF4OC1jTHdEdUpROUFhc2ZNNjVJWjV1bWtmb2UtaEdoYlRhb0dqX1JPa0d3WEJiaXJFdXJ3ak5TV2l2S3h4WjN4S0FLUVRrVXZ3Skx2T0xzdkpxQm90aklYRm51NFp0dkNNZjlVSHQzbkp2ZDBvdm8?oc=5","date":"2025-10-30","type":"pipeline","source":"The Pharma Letter","summary":"Oculis prices $110 million financing - The Pharma Letter","headline":"Oculis prices $110 million financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPVFZscFhMblFhdW5tdEpTcWpMc2RXWmN3c0ttUnZ4RWdCa25SaUt6MzZWMlljOHM4elBKMGs1X01wbm53ZDFPc19YaG0wOXoyUzNiNkVHak5obVF2amtqYzg1NGtCQmQycWh1LXMyX0xhbXF2NVNpbXJSeXV4WEJFRTBYck81eUl2Rl9WNA?oc=5","date":"2025-10-06","type":"trial","source":"pharmaphorum","summary":"Oculis takes second eye disease therapy into pivotal trials - pharmaphorum","headline":"Oculis takes second eye disease therapy into pivotal trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPTTdtajNTZm9fY2dEVWJIN01rZUNOc3lUUHhhQnp2WmpaQnBoZTUwVk01VWFYQy1QeHVEOGxkaVlmMmtfR3ZlZkN6Q3lPUUE4azd4NGJaLTFHNnhhQlEtcHprM2EyWTc3V25vUVU2SFRaWndpM3VtSC05MDBXSktkRTZRQTdvQQ?oc=5","date":"2025-05-01","type":"trial","source":"The Pharma Letter","summary":"Positive Phase II ACUITY trial for Oculis’ OCS-05 - The Pharma Letter","headline":"Positive Phase II ACUITY trial for Oculis’ OCS-05","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPeEE2cWZsU0RTcXVNVjFJbWx6Y292Yk1CSmpETXlwX3V5M0RuSkVCd1RsQk5zdElGUDBYZUhVVkhxbWc0WUlnZm5vQXo4Z3N5T2oyd1RJTVkxRFlpckN1bWdqMGFvbVdMRndYRnpOWmJkTGJCUmNtYnhJMy1EaGRIMXdfVXhvQVN1cWV6a0hrN19hcy1uUUhTcFVDa2ZtRm56UU5EZGVn?oc=5","date":"2025-02-17","type":"pipeline","source":"Greater Geneva Bern area","summary":"Oculis secures USD 100 million to advance its neuroprotective treatment pipeline - Greater Geneva Bern area","headline":"Oculis secures USD 100 million to advance its neuroprotective treatment pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQT2Q4YXJEeHJiQUdvZTlCdl9SZ2U5d01FU3haWGx4LTRoZnV1NWRpUzd0MlVNcHRGdUd3bGhYYWhYankyblhuLTg3U3k5UGh3U1k3WFBuaTIzSGxPOUpPMFA1UmJlN2ZiUTlSNklSakFwaloteVBTSU9fUHFBOE02T19RMjJJTGNlUE5rMXdiTUplSXhSVVdEMFhObGdvbkRDb0ZSeGNiT2x0QnRWWVdMNTVVTk8zZ3ZzaUpZUg?oc=5","date":"2024-08-27","type":"trial","source":"BioSpace","summary":"Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error - BioSpace","headline":"Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPX1ZnMG9ac1l1NUVqWk10cTFLbEFpV0VYeEppQVJVbG1WbW96YjloX2dPOHNvcTZjbEZVRHFLQzY5RzF6Vk1MNF9zTVNiTWx6VHpITUIyX0lBUEdhOFFpRV94R2tHOVBwTlpOOGZDWmMxdjZqaTZiOVllZVV0YmpYV3hLazN6Ql95MTFFZTZwX3dwVWsxN0prY0k2WUZtdHI4ODB3M0s4MnNWa1BLY294SlpwbmpMTHpoTElaWTNaLWk?oc=5","date":"2024-08-13","type":"pipeline","source":"PR Newswire","summary":"Pathalys Pharma Appoints Dr. Bastian Dehmel as Chief Medical Officer - PR Newswire","headline":"Pathalys Pharma Appoints Dr. Bastian Dehmel as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQanh3QV9SSDZuYk1hTVlNdVYtdGRqMjZhcDcwbFZqV01PdEl1SUlpYjAyZlNoWUFhZ212QUZkdzZIUVJHcUZpbzF4dmhmSnFGU1JpcFR0a2FpampzdTd2aWdSTC1BZ21FT05RcHp1Q3VIZnNTYVNtOEVrSVQzcktyaEh1eFh6c256WDZldkxjOGVCeExGX19LOFBlblU?oc=5","date":"2024-06-10","type":"trial","source":"Fierce Biotech","summary":"Oculis sees promise in dry eye disease subgroup, plans phase 3 - Fierce Biotech","headline":"Oculis sees promise in dry eye disease subgroup, plans phase 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNMzFETnBoS0lhbHRGX1pOdndwaVoxSkhCQVFqaHJxXzZ3ZmNmbjZmNE5fNTlkWGxFSlZJbjgyMTZTRjBQU2JNRzlpT1FydGYyTUU2ZXRvTk5BTTQxN3cyeEpkT0V2S3ZUYkVWVjZ5UmlPUmNsVE9MTzNRalk1MlhSN1BZMkExbHhpY090aUg3TDdnWUZYaTZB?oc=5","date":"2024-04-10","type":"pipeline","source":"Contract Pharma","summary":"Oculis Names Dr. Snehal Shah as President of R&D - Contract Pharma","headline":"Oculis Names Dr. Snehal Shah as President of R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE5uM3BURXpOM0hFSS13RzhHb2RGS0QwYzNlR0h0TVBWNDVFNnlvaVVReWpLYXJaMHFoQjNZc0RpekNRS2RQQ1NCZ3NFeVRnMDhvRjAtb0swQ0J3a2QwQUg5OFFkcjV4SHJlR0hXdmoybk5xZw?oc=5","date":"2023-05-23","type":"trial","source":"Clinical Trials Arena","summary":"Oculis’ Stage I trial of OCS-01 eye drops meets its endpoints - Clinical Trials Arena","headline":"Oculis’ Stage I trial of OCS-01 eye drops meets its endpoints","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPSGthMXd2WVBmYW05M2dnc3JsTzJuOW0xSGFOTHUyWTNNbHRleFp4LWNGZjU4UWFmU09ZV0ZRMlRSRUEwb3VJYnFYQVl1UU9QUGlPVkl3cjVpc2xrLVkyMXhDb0loRUhLeHJZSFFma3NGZFNYM0k0VnR0bGU1eWZZbGVkYWFhSUVCQ0ZkU3piX3lXZnBOU3BmTUUxaw?oc=5","date":"2022-10-17","type":"pipeline","source":"Labiotech.eu","summary":"Ophthalmology biopharma company Oculis combines with EBAC - Labiotech.eu","headline":"Ophthalmology biopharma company Oculis combines with EBAC","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}